Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.66 -0.6%	$1.74	$1.41 ▼ $5.01	$9.18M	1.19	27,974 shs	93,479 shs
CYTK Cytokinetics	$37.23 -4.3%	$33.08	$29.31 ▼ $61.38	$4.45B	0.59	1.53 million shs	1.37 million shs
FREQ Frequency Therapeutics	$0.30	$0.58	$0.18 ▼ $16.00	$10.94M	0.84	822,537 shs	309,164 shs
GOSS Gossamer Bio	$1.70 -0.6%	$1.27	$0.66 ▼ $1.89	$386.41M	1.86	1.47 million shs	3.18 million shs
IMAB I-Mab	$2.10 -2.8%	$1.88	$0.60 ▼ $3.08	$171.49M	1.4	391,325 shs	151,326 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	+0.60%	-5.65%	-4.84%	+11.30%	-58.15%
CYTK Cytokinetics	+0.54%	+6.29%	+19.51%	-1.49%	-31.52%
FREQ Frequency Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
GOSS Gossamer Bio	+3.01%	+25.74%	+37.90%	+103.57%	+56.88%
IMAB I-Mab	+0.47%	+5.37%	-12.55%	+154.12%	+42.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	2.9391 of 5 stars	3.5	3.0	0.0	0.0	2.7	0.8	1.3
CYTK Cytokinetics	4.0425 of 5 stars	4.5	1.0	0.0	4.6	2.1	0.8	0.0
FREQ Frequency Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	3.7966 of 5 stars	3.5	1.0	0.0	4.7	2.6	1.7	0.0
IMAB I-Mab	2.871 of 5 stars	3.7	3.0	0.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	833.73% Upside
CYTK Cytokinetics	2.93	Moderate Buy	$70.92	90.50% Upside
FREQ Frequency Therapeutics	0.00	N/A	N/A	N/A
GOSS Gossamer Bio	3.00	Buy	$8.25	385.29% Upside
IMAB I-Mab	3.33	Buy	$6.00	185.71% Upside

Current Analyst Ratings Breakdown

Latest CYTK, FREQ, IMAB, GOSS, and APRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
7/9/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/27/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
6/26/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
6/9/2025	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$71.00 ➝ $53.00
5/29/2025	CYTK Cytokinetics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$103.00 ➝ $84.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/14/2025	CYTK Cytokinetics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00
5/13/2025	CYTK Cytokinetics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$1.50M	6.12	N/A	N/A	$3.55 per share	0.47
CYTK Cytokinetics	$18.47M	240.74	N/A	N/A	($1.15) per share	-32.37
FREQ Frequency Therapeutics	$14.07M	0.78	N/A	N/A	$1.96 per share	0.15
GOSS Gossamer Bio	$114.70M	3.37	N/A	N/A	$0.13 per share	13.08
IMAB I-Mab	$3.89M	44.08	N/A	N/A	$2.47 per share	0.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.96M	-$2.37	N/A	N/A	N/A	-1,095.02%	-68.39%	-55.74%	8/11/2025 (Estimated)
CYTK Cytokinetics	-$589.53M	-$5.29	N/A	N/A	N/A	-3,201.47%	N/A	-43.75%	8/6/2025 (Estimated)
FREQ Frequency Therapeutics	-$81.58M	-$1.89	N/A	N/A	N/A	N/A	-107.67%	-61.40%	N/A
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.81%	-18.63%	8/27/2025 (Estimated)

Latest CYTK, FREQ, IMAB, GOSS, and APRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CYTK Cytokinetics	-$1.32	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	APRE Aprea Therapeutics	-$0.77	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/14/2025	Q1 2025	APRE Aprea Therapeutics	-$0.6543	-$0.66	-$0.0057	-$0.66	N/A	$0.16 million
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
FREQ Frequency Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.90	5.90
CYTK Cytokinetics	N/A	5.99	5.99
FREQ Frequency Therapeutics	N/A	5.81	5.81
GOSS Gossamer Bio	6.70	5.71	5.71
IMAB I-Mab	N/A	22.35	22.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
CYTK Cytokinetics	N/A
FREQ Frequency Therapeutics	13.18%
GOSS Gossamer Bio	81.23%
IMAB I-Mab	38.38%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	13.63%
CYTK Cytokinetics	2.70%
FREQ Frequency Therapeutics	16.80%
GOSS Gossamer Bio	6.70%
IMAB I-Mab	22.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.53 million	4.78 million	No Data
CYTK Cytokinetics	250	119.43 million	116.20 million	Optionable
FREQ Frequency Therapeutics	46	36.52 million	30.39 million	Not Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable

CYTK, FREQ, IMAB, GOSS, and APRE Headlines

Recent News About These Companies

I-Mab buys Bridge Health for $3M-plus to strengthen pivot to CLDN18.2 bispecific

July 18 at 2:45 PM | fiercebiotech.comF

I-Mab boosts givastomig IP portfolio through Bridge Health buy

July 18 at 9:20 AM | thepharmaletter.comT

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health

July 17 at 7:00 AM | globenewswire.com

I-Mab to Present at the BTIG Virtual Biotechnology Conference

July 14, 2025 | finance.yahoo.com

I-Mab (NASDAQ:IMAB) Upgraded by Wall Street Zen to "Buy" Rating

July 14, 2025 | americanbankingnews.com

I-Mab's (IMAB) Buy Rating Reaffirmed at Needham & Company LLC

July 12, 2025 | americanbankingnews.com

I-Mab (NASDAQ:IMAB) Raised to Buy at Wall Street Zen

July 12, 2025 | marketbeat.com

I-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025

July 9, 2025 | msn.com

I-Mab (NASDAQ:IMAB) Given Buy Rating at HC Wainwright

July 9, 2025 | marketbeat.com

Needham & Company LLC Reiterates Buy Rating for I-Mab (NASDAQ:IMAB)

July 9, 2025 | marketbeat.com

I-Mab Reports Encouraging Phase 1b Data for Givastomig in Combination with Nivolumab and mFOLFOX6 at ESMO GI 2025, Confirming 83% Objective Response Rate in Gastric ... - Nasdaq

July 4, 2025 | nasdaq.com

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

July 2, 2025 | globenewswire.com

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research - Morningstar

July 2, 2025 | morningstar.comM

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

June 30, 2025 | globenewswire.com

I-Mab (NASDAQ:IMAB) Price Target Raised to $5.00

June 27, 2025 | marketbeat.com

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

June 26, 2025 | globenewswire.com

I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025

June 18, 2025 | manilatimes.netM

I-Mab Biopharma: I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement

June 13, 2025 | finanznachrichten.de

I-Mab regains compliance with Nasdaq’s listing rule

June 12, 2025 | kalkinemedia.comK

I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement

June 12, 2025 | manilatimes.netM

I-Mab Regains Nasdaq Compliance with Minimum Bid Price

June 12, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK, FREQ, IMAB, GOSS, and APRE Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$1.66 -0.01 (-0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 +0.05 (+2.71%)

As of 04:56 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Cytokinetics NASDAQ:CYTK

$37.23 -1.66 (-4.27%)

Closing price 04:00 PM Eastern

Extended Trading

$37.21 -0.02 (-0.06%)

As of 07:59 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Frequency Therapeutics NASDAQ:FREQ

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Gossamer Bio NASDAQ:GOSS

$1.70 -0.01 (-0.58%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 -0.02 (-1.47%)

As of 06:33 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

I-Mab NASDAQ:IMAB

$2.10 -0.06 (-2.78%)

Closing price 04:00 PM Eastern

Extended Trading

$2.10 +0.00 (+0.24%)

As of 07:17 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time